Lilly China To Double China Staff By End Of Year
This article was originally published in PharmAsia News
Lilly China is ignoring the economic doldrums facing many firms and plans to double its current staff of 1,000 in China by the end of this year. Lilly China is among big pharma company in adding staff in China, with Novartis Pharmaceuticals planning a 20 percent per year staff increase until 2013. Lilly China President David Ricks said driving the staff increase is a need to add sales and distribution workers to enable the company to serve an expanded portion of the population. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.